Drug Profile
Mapracorat
Alternative Names: BAY-865319; BOL-303242-X; ZK-245186Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bausch & Lomb; Bayer HealthCare Pharmaceuticals
- Class Anti-inflammatories; Corticosteroids; Skin disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
- Discontinued Allergic conjunctivitis; Atopic dermatitis; Dry eyes; Ocular inflammation; Ocular pain
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Ointment)
- 31 Aug 2013 Bausch & Lomb completes a phase III trial in Ocular pain & inflammation in USA (NCT01591161)
- 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International